Third-trimester uterine artery Doppler for prediction of adverse outcome in late small-and adequate for-gestational-age fetuses.


Journal

Minerva obstetrics and gynecology
ISSN: 2724-6450
Titre abrégé: Minerva Obstet Gynecol
Pays: Italy
ID NLM: 101777346

Informations de publication

Date de publication:
Oct 2023
Historique:
medline: 29 9 2023
pubmed: 22 3 2023
entrez: 21 3 2023
Statut: ppublish

Résumé

Fetal growth restriction includes all those fetuses that do not reach their own growth potential due to placental insufficiency and therefore at higher risk of adverse perinatal outcomes. Identification and follow-up of these fetuses is essential to decrease this additional risk. Although estimated fetal weight under the 3rd centile and pathological cerebroplacental ratio are the most accepted predictive criteria, some evidence suggests that abnormal uterine artery Doppler may be a useful prognostic parameter in late-onset growth restriction fetuses at the moment of diagnosis. However, its prediction capacity as a standalone parameter is limited. In that context, integrated models of biometric and hemodynamic ultrasound parameters including uterine Doppler have been proposed as an effective approach to stratify the risk and improve perinatal outcomes. Moreover, an association of abnormal uterine artery Doppler and histological findings of placental underperfusion due to vascular obstruction has been described. Finally, it has also been suggested that the evaluation of uterine artery Doppler at third trimester in appropriate-for-gestational-age fetuses could identify cases of subclinical placental insufficiency, but further evidence is needed to define such predictive strategies.

Identifiants

pubmed: 36943257
pii: S2724-606X.23.05229-6
doi: 10.23736/S2724-606X.23.05229-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

440-448

Auteurs

Cristina Mula (C)

BCNatal - Hospital Sant Joan de Déu, Institut Clínic de Ginecologia, Obstetrícia i Neonatologia Fetal (ICGON), i+D Fetal Medicine Research Center, Barcelona, Spain.

Judit Hidalgo (J)

BCNatal - Hospital Sant Joan de Déu, Institut Clínic de Ginecologia, Obstetrícia i Neonatologia Fetal (ICGON), i+D Fetal Medicine Research Center, Barcelona, Spain.

Anna Peguero (A)

BCNatal - Hospital Sant Joan de Déu, Institut Clínic de Ginecologia, Obstetrícia i Neonatologia Fetal (ICGON), i+D Fetal Medicine Research Center, Barcelona, Spain.

Edurne Mazarico (E)

BCNatal - Hospital Sant Joan de Déu, Institut Clínic de Ginecologia, Obstetrícia i Neonatologia Fetal (ICGON), i+D Fetal Medicine Research Center, Barcelona, Spain.

Judit Martinez (J)

BCNatal - Hospital Sant Joan de Déu, Institut Clínic de Ginecologia, Obstetrícia i Neonatologia Fetal (ICGON), i+D Fetal Medicine Research Center, Barcelona, Spain.

Francesc Figueras (F)

BCNatal - Hospital Sant Joan de Déu, Institut Clínic de Ginecologia, Obstetrícia i Neonatologia Fetal (ICGON), i+D Fetal Medicine Research Center, Barcelona, Spain - ffiguera@clinic.cat.

Eva Meler (E)

BCNatal - Hospital Sant Joan de Déu, Institut Clínic de Ginecologia, Obstetrícia i Neonatologia Fetal (ICGON), i+D Fetal Medicine Research Center, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH